Cargando…

Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study

BACKGROUND: Clostridium difficile infection is the most common health-care-associated infection in the USA. We assessed the safety and efficacy of ridinilazole versus vancomycin for treatment of C difficile infection. METHODS: We did a phase 2, randomised, double-blind, active-controlled, non-inferi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vickers, Richard J, Tillotson, Glenn S, Nathan, Richard, Hazan, Sabine, Pullman, John, Lucasti, Christopher, Deck, Kenneth, Yacyshyn, Bruce, Maliakkal, Benedict, Pesant, Yves, Tejura, Bina, Roblin, David, Gerding, Dale N, Wilcox, Mark H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science ;, The Lancet Pub. Group 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483507/ https://www.ncbi.nlm.nih.gov/pubmed/28461207 http://dx.doi.org/10.1016/S1473-3099(17)30235-9

Ejemplares similares

Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin
por: Thorpe, Cheleste M., et al.
Publicado: (2018)

1344. Ridinilazole (RDZ) for Clostridium difficile Infection (CDI): Impact of Diagnostic Method on Outcomes From a Phase 2 Clinical Trial
por: Vickers, Richard, et al.
Publicado: (2018)

668. Quality of Life Changes in Patients with Clostridium difficile Infection (CDI): A Randomized, Double-Blind Trial of Ridinilazole (RDZ) Compared with Vancomycin (VAN)
por: Paul, Sumita, et al.
Publicado: (2019)

Ridinilazole: a novel antimicrobial for Clostridium difficile infection
por: Cho, Jonathan C., et al.
Publicado: (2019)

Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection
por: Bassères, Eugénie, et al.
Publicado: (2016)

1361. Pharmacokinetics and Safety of Ridinilazole (RDZ), a Potential New Therapy for Clostridium difficile Infection (CDI): From Animal Models to Patients
por: Duperchy, Esther, et al.
Publicado: (2018)

2387. Selecting Clostridium difficile Infection (CDI) Outcome Measures Relevant to Public Health Concerns: Experience From a Ridinilazole (RDZ) Phase 2 Trial
por: Vickers, Richard, et al.
Publicado: (2018)

Ridinilazole: a novel, narrow‐spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile
por: Collins, Deirdre A, et al.
Publicado: (2022)

1369. Combined Analysis of the In Vitro Activity of Ridinilazole (RDZ) Against More Than 500 Clostridium difficile (CD) Clinical Isolates and Impact of RDZ on Cell Morphology
por: Duperchy, Esther, et al.
Publicado: (2018)

1774. Ridinilazole (RDZ) for Clostridium difficile infection (CDI): Correlation of In Vitro Spectrum of Activity with Human Gut Microbiome Profiles from a Phase 2 Clinical Trial
por: Vickers, Richard, et al.
Publicado: (2018)

Evaluation of the antimicrobial activity of ridinilazole and six comparators against Chinese, Japanese and South Korean strains of Clostridioides difficile
por: Collins, Deirdre A, et al.
Publicado: (2020)

Clostridium difficile--a moving target
por: Tillotson, Glenn S., et al.
Publicado: (2011)

Ridinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids
por: Qian, Xi, et al.
Publicado: (2020)

Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection
por: Gerding, D. N., et al.
Publicado: (2016)

The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic
por: Mason, Clive S., et al.
Publicado: (2023)

A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections
por: Vickers, Richard, et al.
Publicado: (2015)

Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin
por: Figueroa, Iris, et al.
Publicado: (2012)

SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI
por: Sattar, Abdul, et al.
Publicado: (2015)

A US-based national surveillance study for the susceptibility and epidemiology of Clostridioides difficile isolates with special reference to ridinilazole: 2020–2021
por: Snydman, D. R., et al.
Publicado: (2023)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators
por: Freeman, Jane, et al.
Publicado: (2015)

Vancomycin Enemas as Adjunctive Therapy for Clostridium difficile Infection
por: Malamood, Mark, et al.
Publicado: (2015)

Comparison of Fidaxomicin and Vancomycin for Recurrent Clostridium difficile Colitis
por: Khoo, Teresa, et al.
Publicado: (2017)

The Challenging Conundrum of Diagnosing and Managing Clostridium difficile Infection
por: Gerding, Dale N., et al.
Publicado: (2017)

Clearance of Vancomycin-Resistant Enterococcus Concomitant With Administration of a Microbiota-Based Drug Targeted at Recurrent Clostridium difficile Infection
por: Dubberke, Erik R., et al.
Publicado: (2016)

Oral vancomycin desensitisation to treat Clostridium difficile infection in a vancomycin allergic patient
por: Mahabir, Shanti, et al.
Publicado: (2013)

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence
por: Gerding, Dale N, et al.
Publicado: (2018)

Proteomic Signatures of Clostridium difficile Stressed with Metronidazole, Vancomycin, or Fidaxomicin
por: Maaß, Sandra, et al.
Publicado: (2018)

Economic Barriers in the Treatment of Clostridium difficile Infection With Oral Vancomycin
por: Bunnell, Kristen L., et al.
Publicado: (2017)

Concomitant Vancomycin-Resistant Enterococcus faecium and Clostridium difficile Colitis
por: Mehershahi, Shehriyar, et al.
Publicado: (2021)

Piperacillin/tazobactam/vancomycin: Clostridium difficile colitis: case report
Publicado: (2021)

Treatment of Clostridium difficile infection in mice with vancomycin alone is as effective as treatment with vancomycin and metronidazole in combination
por: Erikstrup, Lise Tornvig, et al.
Publicado: (2015)

Initial Oral Vancomycin vs. Oral Vancomycin After Metronidazole for Severe Clostridium difficile Infection
por: Shah, Sunish, et al.
Publicado: (2017)

525 Epidemiology and burden of recurrent Clostridium difficile infections
por: Sheitoyan-Pesant, Caroline, et al.
Publicado: (2014)

Refractory Clostridium difficile Infection Successfully Treated with Tigecycline, Rifaximin, and Vancomycin
por: Lao, Dominador, et al.
Publicado: (2012)

Safety Analysis of Fidaxomicin in Comparison With Oral Vancomycin for Clostridium difficile Infections
por: Weiss, Karl, et al.
Publicado: (2012)

Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
por: Cornely, Oliver A., et al.
Publicado: (2012)

Therapeutic Success of Rifaximin for Clostridium difficile Infection Refractory to Metronidazole and Vancomycin
por: Tannous, George, et al.
Publicado: (2010)

Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection
por: Nathwani, Dilip, et al.
Publicado: (2014)

Prolonged oral vancomycin for secondary prophylaxis of relapsing Clostridium difficile infection
por: Zhang, Kevin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b169vn4jbm18oh1m383b2a8cj3